Arturo Molina MD - 23 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role: Chief Medical Officer
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Issuer symbol: PTGX
Transactions as of: 23 Jan 2026
Net transactions value: -$1,824,905
Form type: 4
Filing time: 27 Jan 2026, 21:19:50 UTC
Previous filing: 21 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MOLINA ARTURO MD	Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK	/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD	27 Jan 2026	0001398940

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTGX	Common Stock	Sale	$1,083,905	-13,151	-14%	$82.42	84,115	23 Jan 2026	Direct	F1
transaction	PTGX	Common Stock	Options Exercise	$40,200	+5,000	+5.9%	$8.04	89,115	26 Jan 2026	Direct
transaction	PTGX	Common Stock	Sale	$411,400	-5,000	-5.6%	$82.28	84,115	26 Jan 2026	Direct	F2
transaction	PTGX	Common Stock	Options Exercise	$40,200	+5,000	+5.9%	$8.04	89,115	27 Jan 2026	Direct
transaction	PTGX	Common Stock	Sale	$410,000	-5,000	-5.6%	$82.00	84,115	27 Jan 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTGX	Stock Option (right to buy)	Options Exercise	$0	-5,000	-6.6%	$0.000000	70,971	26 Jan 2026	Common Stock	5,000	$8.04	Direct	F3
transaction	PTGX	Stock Option (right to buy)	Options Exercise	$0	-5,000	-7%	$0.000000	65,971	27 Jan 2026	Common Stock	5,000	$8.04	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.665 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.14 to $82.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3	The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.